For patients with advanced prostatic carcinoma who have become resistant to hormone therapy, chemotherapy is probably the most appropriate treatment. Several drug administration modalities and associations with hormonotherapy are analyzed. In a multiple drug (adriamycin, VM 26, 5-fluoro-uracile and cyclophosphamide) chemotherapy trial, 25 out of 31 hormone resistant patients showed objective as well as subjective responses. Survival was significantly higher in this group of patients than in patients who did not respond to this chemotherapy association.